FTC Seeks Input On How PBM Rebating Practices Affect Drug ‘Affordability,’ Access
With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.
You may also be interested in...
Biosimilars Forum Welcomes PBM Transparency Act
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
AAM Calls For FTC Scrutiny Of Pharmacy Benefit Manager Practices
Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.
FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics
Federal Trade Commission’s ‘pro-competitive’ perspective could support conclusion that pharmacy benefit managers serve useful role in lowering drug costs, health policy expert suggests. FTC will get an earful about PBM practices, but ‘those complaints could be an indication that competition is working.’